Cagrilintide vs Semaglutide: Comparing the Amylin and GLP-1 Research Peptides

Cagrilintide and semaglutide come from two different hormone families that are often studied together in metabolic research. This research-only comparison explains how the literature distinguishes them.

What is Cagrilintide?

Cagrilintide is a long-acting amylin analogue. Amylin is a hormone co-secreted with insulin, and cagrilintide is studied as a model for the amylin signalling pathway.

What is Semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist, one of the most characterised molecules in incretin research. It engages an entirely different receptor system than cagrilintide.

Key differences in the research

The difference is the pathway: cagrilintide is studied at the amylin system, semaglutide at the GLP-1 system. Because the two mechanisms are distinct, researchers examine whether combining them produces effects that neither shows alone.

Why they are studied together

The amylin-plus-GLP-1 combination is a major theme in current metabolic research, and the two compounds are the reference molecules for it. Tirzepatide and retatrutide are often added to compare multi-pathway approaches.

Handling and storage

Both are lyophilised and reconstituted with bacteriostatic water. Follow the GLP-1 reconstitution guide, keep them refrigerated, and use the reconstitution calculator.

Quality and verification

Because both are modified peptides, purity data is important. Understanding how purity is verified helps you evaluate each Certificate of Analysis before use.

Research use only. This article is educational and is not medical, legal, or financial advice. The compounds discussed are not approved for human or veterinary use, consumption, or therapeutic application.